Jade Biosciences Files 8-K on Asset Disposition
Ticker: JBIO · Form: 8-K · Filed: May 14, 2025 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Jade Biosciences, INC. (JBIO) |
| Form Type | 8-K |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition-disposition, financials, corporate-event
TL;DR
Jade Bio (formerly Aerovate) filed an 8-K on 5/14/25 detailing asset disposition & financials.
AI Summary
On May 14, 2025, Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K report. The filing indicates a completion of acquisition or disposition of assets, results of operations and financial condition, and includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Waltham, MA.
Why It Matters
This 8-K filing signals a significant corporate event for Jade Biosciences, potentially involving the sale or acquisition of assets, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — 8-K filings detailing asset disposition can introduce uncertainty about the company's strategic direction and future financial performance.
Key Players & Entities
- Jade Biosciences, Inc. (company) — Registrant
- Aerovate Therapeutics, Inc. (company) — Former company name
- May 14, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Waltham, MA (location) — Address of principal executive offices
FAQ
What specific assets were acquired or disposed of by Jade Biosciences, Inc.?
The filing indicates 'Completion of Acquisition or Disposition of Assets' but does not specify the assets involved in this 8-K.
What is the nature of the 'Results of Operations and Financial Condition' reported?
The 8-K filing lists 'Results of Operations and Financial Condition' as an item but does not provide the details within this summary.
When did Jade Biosciences, Inc. change its name from Aerovate Therapeutics, Inc.?
The filing states the former company name was Aerovate Therapeutics, Inc. and the date of name change was January 3, 2020.
What is Jade Biosciences, Inc.'s standard industrial classification?
Jade Biosciences, Inc.'s Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Jade Biosciences, Inc.'s principal executive offices located?
Jade Biosciences, Inc.'s principal executive offices are located at 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding Jade Biosciences, Inc. (JBIO).